Roche’s Avastin receives approval from the EMA

As reported by the Pharma Times, Roche’s ovarian cancer drug, Avastin has received approval from the European Medicines Agency (EMA).

Avastin has been approved for the treatment of advanced ovarian cancer when combined with standard chemotherapy. It will now be available to patients in England.

The ovarian cancer drug has been shown to stop disease progression for six months longer than chemotherapy does. Speaking of the news, Dr Timothy Perren, Consultant Medical Oncologist at St James’ University Hospital stated,  “Avastin is the first new drug that has been shown to improve outcomes for women with advanced ovarian cancer for the past 15 years. Ovarian cancer currently has the worst outcomes of all gynaecological cancers and halting disease progression for six months is an important step forward in treating this condition.”

Avastin is also approved in the EU for the treatment of the advanced stages of five common cancer types – colorectal, breast, lung and kidney.

Click here to search our drug development jobs now.

Posted in: General, News
CK Logo in place of featured image